Clinical Trials Logo

Filter by:
NCT ID: NCT06247657 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours

Start date: January 3, 2024
Phase: Phase 1
Study type: Interventional

This is the first in human study of BL0006, and the primary objective is to evaluate the safety and tolerability of BL0006 as a single agent in patients with advanced solid tumors.

NCT ID: NCT06247605 Recruiting - Clinical trials for Small Cell Lung Carcinoma

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Start date: October 26, 2023
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.

NCT ID: NCT06247579 Recruiting - Depression, Anxiety Clinical Trials

Effects of Dietary Polystyrene Microplastics on Anxiety- and Depression-like Behaviors

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to explore the potential impact of dietary polystyrene microplastics on anxiety- and depression-like behaviors in resident physicians. Specifically, the study aims to address two key questions: 1. Can dietary polystyrene microplastics induce alterations in the human gut microbiome? 2. Can dietary polystyrene microplastics exacerbate anxiety- and depression-like behaviors? Participants will be divided into two groups based on their habitual eating practices: The control group, consisting of resident physicians, will use non-disposable plastic tableware (NDPT) provided by hospital canteens for two months. In contrast, the exposure group, also comprising resident physicians, will use disposable plastic tableware (DPT) made of polystyrene, provided by the same hospital canteens, over the same period.

NCT ID: NCT06247566 Completed - Clinical trials for Primary Aldosteronism With Bilateral Adrenal Lesions

68Ga-Pentixafor PET/CT for Guiding Surgical Treatment of Primary Aldosteronism With Bilateral Adrenal Lesions

Start date: November 1, 2021
Phase:
Study type: Observational

Screening potential candidates who may benefit from surgery remains challenging for patients diagnosed with primary aldosteronism (PA) accompanied by bilateral adrenal lesions. Although adrenal venous sampling is currently the gold standard, it is a technically cumbersome, challenging, and difficult-to-interpret invasive procedure that requires a cutting-edge facility and radiologists with a high level of expertise, which restricts its widespread use. The present study aimed to assess the comprehensive effect of 68Ga-pentixafor positron emission tomography/computer tomography (PET/CT) on guiding surgical treatments for PA patients with bilateral adrenal lesions.

NCT ID: NCT06247046 Recruiting - Clinical trials for Irritable Bowel Syndrome With Diarrhea

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D

Start date: March 16, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Live SK08 Powder compared with placebo in the treatment of participants with irritable bowel syndrome with diarrhea.

NCT ID: NCT06246695 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

Start date: October 27, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to assess the effect of rifampicin and itraconazole, on the pharmacokinetics (PK) of Jaktinib in healthy Volunteers.

NCT ID: NCT06246630 Recruiting - Clinical trials for Advanced Pancreatic Neuroendocrine Tumor

In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Start date: April 3, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic Pancreatic neuroendocrine tumors. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response

NCT ID: NCT06246617 Recruiting - Thoracic Surgery Clinical Trials

Valuate the Clinical Performance and Safety of da Vinci SP Surgical System

Start date: October 25, 2023
Phase: N/A
Study type: Interventional

This clinical trial is a real-world study to evaluate the clinical performance and safety of da Vinci SP Surgical System ("SP single-port robot" for short) for single-port robot-assisted thoracic surgeries in the real world, providing a real world evidence for clinical application of the product in the Chinese population.

NCT ID: NCT06246461 Completed - Capecitabine Clinical Trials

The Therapeutic Effect of Different Doses of Capecitabine

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.Different administration regimens of capecitabine were given, and the treatment course was appropriately extended. The therapeutic effect and incidence of adverse reactions were observed.

NCT ID: NCT06246344 Recruiting - Rectal Cancer Clinical Trials

MRI Guided SIB Radiotherapy in Neoadjuvant Therapy for Advanced Rectal Cancer

Start date: December 1, 2023
Phase:
Study type: Observational

Colorectal cancer has an annual incidence surpassing 700,000 cases globally, ranking as the fourth most prevalent cancer with the second-highest mortality rate. Rectal cancer accounts for approximately one-third of newly diagnosed colorectal cancer cases. Stages II (cT3-4/N0) and III (cT1-4/N1-3) rectal cancer are commonly classified as Locally Advanced Rectal Cancer (LARC), characterized by a high risk of local recurrence post-surgery. Neoadjuvant chemoradiotherapy (CRT) combined with Total Mesorectal Excision Surgery (TME) has reduced the 5-year local recurrence rate in LARC from 25% to 5%-10%. Currently, neoadjuvant CRT+TME+postoperative adjuvant chemotherapy effectively controls local recurrence in LARC. However, it is associated with low Pathological Complete Regression (pCR) rates, suboptimal sphincter preservation, increased distant metastasis, heterogeneous adherence to adjuvant chemotherapy, and limited long-term survival benefits. Further optimization of neoadjuvant treatment strategies holds promise for promoting tumor regression and improving prognosis. In neoadjuvant therapy, the extent of rectal tumor regression is highly dependent on radiotherapy, with higher radiation doses correlating with increased rates of pathological regression. This study aims to investigate the role of MRI-guided radiotherapy with a simultaneous integrated boost in enhancing tumor pCR in neoadjuvant treatment for locally advanced rectal cancer.